Andilab, Heidelyn .

HRN: 16-95-54  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/21/2025
CEFUROXIME 500MG (TAB)
06/21/2025
06/28/2025
ORAL
500 MG/TAB
BID
S/P NSVD, THINLY MSAF
Pending Pharmacy Acceptance 

 Indication:  Prophylaxis    Type of Infection:  Reproductive Tract    Compliance to guidelines: